Skip to main content

Table 3 In-field tumor response rates of the target lesions after tomotherapy and concurrent capecitabine treatment

From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer

Target lesions CR PR SD PD
Pancreatic mass (n = 15) 0 (0) 8 (53.3) 7 (46.7) 0 (0)
Regional lymph nodes (n = 4) 0 (0) 1 (25.0) 3 (75) 0 (0)
Distant metastasis (n = 7) 0 (0) 2 (28.6) 5 (71.4) 0 (0)
Liver (n = 6) 0 (0) 1 (16.7) 5 (83.3) 0 (0)
Lung (n = 1) 0 (0) 1 (100) 0 (0) 0 (0)
Overall (n = 26) 0 (0) 11 (42.3) 15 (57.7) 0 (0)
  1. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
  2. Numbers in parentheses are percentages